Emkay Global has reaffirmed a BUY rating on HDFC Life Insurance, assigning a September 2026 target price of Rs 850.

In its latest research, Choice Equity Broking maintains BUY recommendation on technology major Infosys, revising the target price to Rs 1,810—implying a potential upside of 25.7% from current level

India’s fintech revolution has matured into a trillion-dollar opportunity by 2030, reshaping how hundreds of millions manage, borrow, invest, and insure their finances.

India’s biotechnology industry, one of the fastest-expanding sectors globally, is blazing new trails across healthcare, pharmaceuticals, and sustainability.

Motilal Oswal Financial Services has reiterated its BUY call on Laurus Labs, highlighting a robust earnings trajectory and strategic capital deployment in CDMO and generics segments.

Deven Choksey Research has reaffirmed a BUY call on UltraTech Cement, identifying significant growth drivers and robust financial resilience.